Skip to main content

Advertisement

Table 1 Baseline characteristics of 211 participants

From: Performance of the tuberculin skin test and interferon-γ release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population

Characteristic All participants n= 211 Immunocompetent n= 94 Immunocompromised n= 117 p
Age, median (range) 55 (19-98) 53 (19-98) 55 (19-93) 0.13
Male/female 97/114 45/49 52/65 0.62
BMI (median, IQR) 21.6 (19.5-24.5) 21.2 (18.8-23.9) 22.2 (19.9-25.0) 0.09
History of smoking 34 (16) 14 (15) 20 (17) 0.19
History of recent TB contact     
   Negative 181 (85.8) 85 (90.4) 96 (82.1)  
   Positive 2 (0.9) 2 (2.1) 0 (0) 0.22*
   Unknown 28 (13.3) 7 (7.4) 21 (17.9)  
Presence of TB scar on chest X-ray 7 (3.3) 5 (5.3) 2 (1.7) 0.25
Laboratory findings (median, IQR)     
   WBC (103/uL) 7350 (5480-10570) 7260 (5900-9380) 7430 (5030-11280) 0.89
   Haemoglobin (g/dL) 11.1 (9.5-12.7) 11.9 (10.75-13.4) 10.6 (9.2-12.0) < 0.001
   Platelets (103/uL) 272 (196-380) 277 (210-394) 266 (170-379) 0.16
   Lymphocytes (103/uL) 1410 (860-1890) 1670 (1155-2085) 1230 (755-1700) < 0.001
   Total protein (g/dL) 6.8 (6.1-7.38) 7.2 (6.7-7.6) 6.5 (5.7-7.0) < 0.001
   Albumin (g/dL) 3.6 (2.9-4.2) 4.0 (3.2-4.4) 3.2 (2.8-3.9) < 0.001
   Cholesterol (mg/dL) 152 (122-184) 160 (128-184) 149 (117-182) 0.14
Disease associated with immunosuppression 117 (55)    
   Diabetes 23 (11)    
   Solid cancer treated with anticancer chemotherapy 28 (13)    
   Haematologic malignant disease 7 (3)    
   Transplantation 11(5)    
   ESRD on renal replacement therapy 6 (3)    
   Liver cirrhosis, Child-Pough class C 1 (0.5)    
   HIV infection 1 (0.5)    
   Treated with immunosuppressive drugs† 40 (19)    
  1. Data are presented as numbers (percentages) unless otherwise indicated.
  2. BMI, body mass index; ESRD, end-stage renal disease; IQR, interquartile range; TB, tuberculosis; WBC, white blood cells.
  3. *p 0.22 for the difference in the history of recent TB contact, excluding participants whose history of recent TB contact was unknown.
  4. †Patients receiving systemic corticosteroids (at least 15 mg of prednisone per day for more than one month) or combination therapy with low dose corticosteroids and other immunosuppressants including azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide.